Overview

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes

Status:
NOT_YET_RECRUITING

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

This is a randomised, open-label, multicenter, active-controlled, parallel-design, phase III clinical trial. The purpose of this study to compare the efficacy and safety of Insulin Degludec/Liraglutide Injection with XULTOPHY® once daily via subcutaneous injection in Chinese Subjects with Type 2 Diabetes.

Phase:

PHASE3

Details

Lead Sponsor:

Tonghua Dongbao Pharmaceutical Co.,Ltd

Treatments:

IDegLira
Xultophy